Shore, Neal http://orcid.org/0000-0001-5767-0548
Zurth, Christian
Fricke, Robert
Gieschen, Hille
Graudenz, Kristina
Koskinen, Mikko
Ploeger, Bart
Moss, Jonathan
Prien, Olaf
Borghesi, Gustavo
Petrenciuc, Oana
Tammela, Teuvo L.
Kuss, Iris
Verholen, Frank
Smith, Matthew R.
Fizazi, Karim
Clinical trials referenced in this document:
Documents that mention this clinical trial
Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial
https://doi.org/10.2217/fon-2020-1291
Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
https://doi.org/10.1007/s11523-019-00674-0
The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the Medical Data Vision claims database in Japan
https://doi.org/10.1080/03007995.2019.1619543
Funding for this research was provided by:
Bayer HealthCare
Orion Pharma
Article History
First Online: 30 September 2019
Compliance with Ethical Standards
:
: This work was supported by Bayer HealthCare and Orion Pharma.
: Dr. Shore reports personal fees from Ferring, Bayer, Amgen, Janssen, Dendreon, Tolmar, Astellas, Pfizer, AstraZeneca, Genentech/Roche, Myovant Sciences, Merck, AstraZeneca, Bristol Meyers Squibb, and Nymox outside the submitted work. Drs. Zurth, Fricke, Gieschen, Graudenz, Ploeger, Prien, Borghesi, Petrenciuc, and Kuss report employment by and stock ownership in Bayer. Dr. Koskinen reports employment by and stock ownership in Orion. Dr. Moss reports personal fees from Akari, AstraZeneca, Bayer, Carrick Therapeutics, Debiopharm, Orphazym, Proveca, Richmond Pharmacology, and the University of Leicester outside the submitted work. Dr. Tammela reports personal fees from Janssen, and grants and personal fees from Bayer, Lidds AB, and Astellas, outside the submitted work. Dr. Verholen reports employment by Bayer. Dr. Smith reports personal fees from Amgen, Astellas, Bayer, Clovis, Gilead, Janssen, Lilly, Novartis, and Pfizer, outside the submitted work. Dr. Fizazi reports personal fees from Amgen, Astellas, AstraZeneca, Bayer, Clovis, Curevac, ESSA, Janssen, Orion Pharma, Roche/Genentech, and Sanofi outside the submitted work.
: Informed consent was obtained from all individual participants in the study.